Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Palivizumab for Prophylaxis Against Respiratory Syncytial Virus Infection in Children With Cystic Fibrosis." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431470/all/images/tooltip-triangle.png. Accessed 15 May 2024.
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431470/all/images/tooltip-triangle.png. Accessed May 15, 2024.
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431470/all/images/tooltip-triangle.png
Palivizumab for Prophylaxis Against Respiratory Syncytial Virus Infection in Children With Cystic Fibrosis [Internet]. In: Cochrane Abstracts. [cited 2024 May 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431470/all/images/tooltip-triangle.png.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
ID - 431470
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431470/all/images/tooltip-triangle.png
DB - Evidence Central
DP - Unbound Medicine
ER -